Market Overview

UPDATE: Stifel Nicolaus Initiates Geron Corporation at Buy with $4 PT; Oncology Refocus Paying Off

Share:
Related GERN
Morning Market Losers
Benzinga's Top #PreMarket Losers

Stifel Nicolaus initiated coverage on Geron Corporation (NASDAQ: GERN) with a Buy rating and a price target of $4 a share.

Stifel Nicolaus noted, "We anticipate positive proof-of-concept data for Geron's two oncology assets to reignite investor interest. In our opinion, six Phase 2 data readouts over the next six to nine months should validate Imetelstat and GRN1005 as compelling, differentiated oncology clinical candidates with large commercial opportunities. We believe positive news flow will yield significant stock price appreciation for GERN."

Geron Corporation closed at $2.44 on Wednesday.

Latest Ratings for GERN

DateFirmActionFromTo
Apr 2015OppenheimerInitiates Coverage onOutperform
Jun 2014MLV & Co.UpgradesHoldBuy
Mar 2014NeedhamDowngradesBuyHold

View More Analyst Ratings for GERN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GERN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters